Oncology Analytics, Inc. provides health plans, providers and patients with an evidence-based, technology-driven approach to utilization management, which is purpose-built for oncology. Used by physicians to support over 3.5 million health plan members in the US and Puerto Rico, the Oncology Analytics e-Prior Authorization platform is updated daily to accurately reflect more than 6,000 oncology treatment protocols for anti-cancer treatment across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care. The company's real-world evidence analytics is based on tens of thousands of annual chemotherapeutic cases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/05/18 | $21,000,000 | Series B |
BlueCross BlueShield Venture Partners McKesson Ventures Sandbox Advantage Fund | undisclosed |
| 05/26/20 | $28,000,000 | Series C |
Baird Capital Blue Venture Fund McKesson Ventures | undisclosed |
